When should urate‑lowering therapy be initiated after an acute gout flare resolves, and can it be started concurrently with flare treatment?

When to Start ULT After Acute Gout Flare

You can start urate-lowering therapy (ULT) during an active gout flare rather than waiting for it to resolve. The 2020 American College of Rheumatology guidelines conditionally recommend initiating ULT during a gout flare over waiting for flare resolution 1.

Key Recommendation

The traditional practice of waiting for flare resolution before starting ULT is no longer necessary. When the decision has been made that ULT is indicated, you can proceed with initiation even while the patient is actively flaring, provided you use appropriate anti-inflammatory prophylaxis.

Critical Implementation Strategy

When starting ULT (whether during or after a flare):

• Start with low-dose allopurinol (≤100 mg/day, even lower with CKD stage ≥3) as first-line agent 1
• Always initiate concomitant anti-inflammatory prophylaxis (colchicine, NSAIDs, or prednisone/prednisolone) - this is a strong recommendation 1
• Continue prophylaxis for 3-6 months minimum (not less than 3 months) 1
• Titrate ULT dose gradually to target serum urate <6 mg/dL

Evidence Supporting Concurrent Initiation

Multiple meta-analyses confirm that starting ULT during an acute flare does not:

• Prolong the current episode 2, 3
• Worsen pain scores by day 10 2, 3
• Increase inflammatory markers (ESR, CRP) 2, 3, 4
• Increase recurrence rates within 30 days 2, 3, 4

Recent data from 2024 demonstrates that with proper treat-to-target strategies and optimal prophylaxis, flare risk during ULT initiation is similar between allopurinol and febuxostat 5.

Important Caveats

The conditional (not strong) recommendation reflects moderate certainty evidence - meaning this approach is reasonable but not mandatory. The key distinction from older practice is that you don't need to delay ULT if the decision to start has been made.

Prophylaxis is non-negotiable: The ability to safely start ULT during a flare depends entirely on concurrent anti-inflammatory prophylaxis. Without prophylaxis, initiating ULT significantly increases flare risk 6.

Patient factors predicting higher flare risk during ULT initiation include 5:

• Younger age
• Higher baseline serum urate
• Absence of tophi

Practical Algorithm

1. Treat the acute flare with colchicine, NSAIDs, or corticosteroids
2. If ULT is indicated (recurrent gout ≥2 episodes/year, tophi, chronic kidney disease, or urolithiasis), start immediately - don't wait
3. Begin low-dose allopurinol (≤100 mg/day)
4. Start prophylaxis simultaneously (preferably colchicine 0.6 mg daily or twice daily if tolerated)
5. Continue prophylaxis for 3-6 months minimum
6. Titrate allopurinol gradually every 2-4 weeks to achieve target serum urate

This approach improves medication adherence 4 and eliminates unnecessary delays in achieving long-term disease control.